Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York City. CEO Ian McDonald and CSO Jan Torleif Pedersen will present on Thursday, June 5, 2025, at 8:10 AM ET.
The presentation will be available via webcast on the company's investor relations website, with replay access for 60 days. Investors can schedule one-on-one meetings through Jefferies representatives.
Bright Minds Biosciences (NASDAQ: DRUG), un'azienda che sviluppa agonisti selettivi del 5-HT2 per il trattamento dell'epilessia resistente ai farmaci, della depressione e dei disturbi del SNC, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025 a New York City. Il CEO Ian McDonald e il CSO Jan Torleif Pedersen presenteranno il giovedì 5 giugno 2025 alle 8:10 AM ET.
La presentazione sarà disponibile in webcast sul sito web per gli investitori dell'azienda, con accesso alla replica per 60 giorni. Gli investitori possono prenotare incontri individuali tramite i rappresentanti di Jefferies.
Bright Minds Biosciences (NASDAQ: DRUG), una empresa que desarrolla agonistas selectivos de 5-HT2 para tratar la epilepsia resistente a medicamentos, la depresión y trastornos del SNC, ha anunciado su participación en la Conferencia Global de Salud Jefferies 2025 en la ciudad de Nueva York. El CEO Ian McDonald y el CSO Jan Torleif Pedersen presentarán el jueves 5 de junio de 2025 a las 8:10 AM ET.
La presentación estará disponible vía webcast en el sitio web de relaciones con inversores de la empresa, con acceso a la repetición durante 60 días. Los inversores pueden programar reuniones individuales a través de los representantes de Jefferies.
Bright Minds Biosciences (NASDAQ: DRUG)는 약물 내성 간질, 우울증 및 중추신경계 질환 치료를 위한 선택적 5-HT2 작용제를 개발하는 회사로, 2025년 제퍼리스 글로벌 헬스케어 컨퍼런스에 뉴욕시에서 참여한다고 발표했습니다. CEO Ian McDonald와 CSO Jan Torleif Pedersen가 2025년 6월 5일 목요일 오전 8시 10분(동부 시간)에 발표할 예정입니다.
발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 60일 동안 다시보기 가능합니다. 투자자는 제퍼리스 담당자를 통해 일대일 미팅을 예약할 수 있습니다.
Bright Minds Biosciences (NASDAQ : DRUG), une société développant des agonistes sélectifs 5-HT2 pour le traitement de l'épilepsie résistante aux médicaments, de la dépression et des troubles du SNC, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025 à New York. Le PDG Ian McDonald et le directeur scientifique Jan Torleif Pedersen présenteront le jeudi 5 juin 2025 à 8h10 ET.
La présentation sera disponible en webcast sur le site des relations investisseurs de la société, avec un accès au replay pendant 60 jours. Les investisseurs peuvent planifier des réunions individuelles via les représentants de Jefferies.
Bright Minds Biosciences (NASDAQ: DRUG), ein Unternehmen, das selektive 5-HT2-Agonisten zur Behandlung von medikamentenresistenter Epilepsie, Depression und ZNS-Erkrankungen entwickelt, hat seine Teilnahme an der Jefferies Global Healthcare Conference 2025 in New York City angekündigt. CEO Ian McDonald und CSO Jan Torleif Pedersen werden am Donnerstag, den 5. Juni 2025, um 8:10 Uhr ET präsentieren.
Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiedergabemöglichkeit von 60 Tagen. Investoren können Einzelgespräche über Jefferies-Vertreter vereinbaren.
- None.
- None.
NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif Pedersen, Chief Scientific Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:
| Date: | Thursday, June 5, 2025 |
| Time: | 8:10m ET |
| Webcast: | Click Here |
To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at healthcareconference@jefferies.com.
The live and archived webcast will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
FAQ
When is Bright Minds Biosciences (DRUG) presenting at the 2025 Jefferies Healthcare Conference?
Who will be presenting for Bright Minds Biosciences (DRUG) at the Jefferies conference?
What therapeutic areas does Bright Minds Biosciences (DRUG) focus on?
How can investors access the Bright Minds Biosciences (DRUG) Jefferies conference presentation?
